Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Pathogens cause around two million cancer cases worldwide each year. Ninety percent of these cases are attributable to Helicobacter pylori (H Pylori), hepatitis B virus (HBV), hepatitis C virus (HCV),…  
  • There are nearly 14.5 million people in the U.S. living with a history of cancer.  
  • The overall five-year survival rate for women with invasive breast cancer is now 89 percent.  
  • Because of advances in treatment, the 5-year survival rate for people with actue lymphocytic leukemia has increased from 38% in 1974-1976 to 65% in 1995-2001.  
  • Cancer patients in the U.S. experience greater survival gains than those in European countries, and the value of additional gains exceeds the additional cost of care in the U.S.